{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:53:29Z","timestamp":1789458809468,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Asymptomatic patients with follicular lymphoma (FL) and a low tumour burden can be followed without initial therapy, a strategy called watchful waiting (WW). Prediction of the time to treatment (TTT) is still a challenge. We investigated the prognostic value of baseline total metabolic tumour volume (TMTV) and whole-body total lesion glycolysis (WB-TLG) to predict TTT in patients with FL on WW.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a retrospective study of 54 patients with FL (grade 1\u20133a) diagnosed between June 2013 and December 2019, staged with FDG PET\/CT, and managed on WW. Median age was 62\u00a0years (range 34\u201385), stage was advanced (III\u2013IV) in 57%, and FLIPI score was intermediate to high (\u2265\u20092) in 52% of the patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median TMTV and WB-TLG were 7.1 and 43.3, respectively. With a median follow-up of 59\u00a0months, 41% of patients started immuno-chemotherapy. The optimal cut-points to identify patients with TTT within 24\u00a0months were 14 for TMTV (AUC 0.70; 95% CI 51\u201388) and 64 for WB-TLG (AUC 0.71; 95% CI 52\u201389) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.005). The probability of not having started treatment within 24\u00a0months was 87% for TMTV\u2009&lt;\u200914 and 53% for TMTV\u2009\u2265\u200914 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.005). TMTV was independent of the FLIPI score for TTT prediction. Patients with both FLIPI\u2009\u2265\u20092 and TMTV\u2009\u2265\u200914 had only an 18% probability of not having started treatment at 36\u00a0months, while this probability was 75% in patients with TMTV\u2009&lt;\u200914.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Metabolic tumour volume parameters may add information to clinical scores to better predict TTT and better stratify patients for interventional studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-022-04138-3","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T07:05:53Z","timestamp":1656745553000},"page":"2783-2791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-2898","authenticated-orcid":false,"given":"Lucia","family":"Leccisotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Maccora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"Malafronte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"D\u2019Al\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Maiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Rufini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hohaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"key":"4138_CR1","doi-asserted-by":"crossref","unstructured":"Barrington SF, et al. (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32(27):3048\u20133058","DOI":"10.1200\/JCO.2013.53.5229"},{"issue":"2","key":"4138_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R et al (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328\u2013354","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"4138_CR3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P et al (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 15(3):1110\u20131117","journal-title":"J Clin Oncol"},{"issue":"4","key":"4138_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s11307-020-01474-z","volume":"22","author":"CN Burggraaff","year":"2020","unstructured":"Burggraaff CN et al (2020) Optimizing workflows for fast and reliable metabolic tumor volume measurements in diffuse large B cell lymphoma. Mol Imaging Biol 22(4):1102\u20131110","journal-title":"Mol Imaging Biol"},{"issue":"27","key":"4138_CR5","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"13","key":"4138_CR6","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1158\/1078-0432.CCR-16-0783","volume":"22","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS et al (2016a) Molecular profile and FDG-PET metabolic volume at staging in DLBCL-response. Clin Cancer Res 22(13):3414\u20133415","journal-title":"Clin Cancer Res"},{"issue":"15","key":"4138_CR7","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","volume":"22","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS et al (2016b) Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clin Cancer Res 22(15):3801\u20133809","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4138_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2967\/jnumed.116.180406","volume":"58","author":"AS Cottereau","year":"2017","unstructured":"Cottereau AS et al (2017) Baseline total metabolic tumor volume measured with fixed or different adaptive thresholding methods equally predicts outcome in peripheral T cell lymphoma. J Nucl Med 58(2):276\u2013281","journal-title":"J Nucl Med"},{"issue":"22","key":"4138_CR9","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1182\/blood-2017-11-816298","volume":"131","author":"AS Cottereau","year":"2018","unstructured":"Cottereau AS et al (2018) Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA\/FIL study. Blood 131(22):2449\u20132453","journal-title":"Blood"},{"issue":"6","key":"4138_CR10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjh.16489","volume":"189","author":"S Ekberg","year":"2020","unstructured":"Ekberg S et al (2020) Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century: a Swedish lymphoma register study. Br J Haematol 189(6):1083\u20131092","journal-title":"Br J Haematol"},{"issue":"3","key":"4138_CR11","first-page":"272","volume":"3","author":"SA Esfahani","year":"2013","unstructured":"Esfahani SA et al (2013) Baseline total lesion glycolysis measured with (18)F-FDG PET\/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging 3(3):272\u2013281","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"27","key":"4138_CR12","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M et al (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555\u20134562","journal-title":"J Clin Oncol"},{"issue":"12","key":"4138_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/ajh.24200","volume":"90","author":"A Freedman","year":"2015","unstructured":"Freedman A (2015) Follicular lymphoma: 2015 update on diagnosis and management. Am J Hematol 90(12):1171\u20131178","journal-title":"Am J Hematol"},{"issue":"2","key":"4138_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s00259-018-4200-3","volume":"46","author":"H Ilyas","year":"2019","unstructured":"Ilyas H et al (2019) Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma? Eur J Nucl Med Mol Imaging 46(2):520\u2013521","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"4138_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","volume":"52","author":"HJ Im","year":"2018","unstructured":"Im HJ et al (2018) Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl Med Mol Imaging 52(1):5\u201315","journal-title":"Nucl Med Mol Imaging"},{"issue":"5","key":"4138_CR16","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1182\/bloodadvances.2020002690","volume":"5","author":"L Kostakoglu","year":"2021","unstructured":"Kostakoglu L et al (2021) End-of-treatment PET\/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv 5(5):1283\u20131290","journal-title":"Blood Adv"},{"issue":"26","key":"4138_CR17","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK et al (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 31(26):3272\u20133278","journal-title":"J Clin Oncol"},{"issue":"1","key":"4138_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clml.2019.09.609","volume":"20","author":"A Major","year":"2020","unstructured":"Major A et al (2020) Evaluating novel PET-CT functional parameters TLG and TMTV in differentiating low-grade versus grade 3A follicular lymphoma. Clin Lymphoma Myeloma Leuk 20(1):39\u201346","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"4138_CR19","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M et al (2014) Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging 41(6):1113\u20131122","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"30","key":"4138_CR20","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M et al (2016) Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol 34(30):3618\u20133626","journal-title":"J Clin Oncol"},{"key":"4138_CR21","doi-asserted-by":"publisher","first-page":"20210448","DOI":"10.1259\/bjr.20210448","volume":"94","author":"M Meignan","year":"2021","unstructured":"Meignan M et al (2021) Total tumor burden in lymphoma: an evolving strong prognostic parameter. Br J Radiol 94:20210448","journal-title":"Br J Radiol"},{"issue":"3","key":"4138_CR22","first-page":"83","volume":"102","author":"E Sabattini","year":"2010","unstructured":"Sabattini E et al (2010) WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 102(3):83\u201387","journal-title":"Pathologica"},{"issue":"11","key":"4138_CR23","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","volume":"41","author":"M Sasanelli","year":"2014","unstructured":"Sasanelli M et al (2014) Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging 41(11):2017\u20132022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"4138_CR24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P et al (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258\u20131265","journal-title":"Blood"},{"issue":"31","key":"4138_CR25","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","volume":"30","author":"P Solal-C\u00e9ligny","year":"2012","unstructured":"Solal-C\u00e9ligny P et al (2012) Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 30(31):3848\u20133853","journal-title":"J Clin Oncol"},{"issue":"3","key":"4138_CR26","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.ijrobp.2010.12.055","volume":"82","author":"M Werner-Wasik","year":"2012","unstructured":"Werner-Wasik M et al (2012) What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys 82(3):1164\u20131171","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4138_CR27","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.2147\/CMAR.S216445","volume":"11","author":"Y Zhou","year":"2019","unstructured":"Zhou Y et al (2019) Prognostic values of baseline, interim and end-of therapy. Cancer Manag Res 11:6871\u20136885","journal-title":"Cancer Manag Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04138-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04138-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04138-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:02:53Z","timestamp":1688212973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04138-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4138"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04138-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"31 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participation"}},{"value":"This retrospective observational study involving human participants was in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Ethics Committee of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universit\u00e0 Cattolica del Sacro Cuore approved this study (ID 3834\/2021).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}